Cambridge, UK-based Syndex Bio has announced on Monday the introduction of its proprietary mcPCR™ (methyl-copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) meeting in Orlando, Florida, alongside the close of an oversubscribed $15.5 million seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures and Meltwind Advisory LLP.
Early BioNTech mRNA breast cancer trial delivers surprise in longtime disease control
Latest NewsA study recently published in Nature on the use of mRNA “vaccines” targeting cancer neoantigens in triple-negative breast cancer (TNBC) has generated considerable attention in scientific circles. However, with only 14 patients treated in this Phase I trial, it is far too early to declare a breakthrough. Still, the highly encouraging data breathe new life into a cancer vaccine approach that in recent years had fallen behind antibodies, ADCs and checkpoint inhibitors.
Angelini partners with Quiver on AI-driven discovery in genetic epilepsies
Latest NewsItaly’s Angelini Pharma has signed a multi-year research collaboration and licensing agreement with Massachusetts-based Quiver Bioscience to discover new treatments for genetic epilepsies, including developmental and epileptic encephalopathies (DEEs). Under the agreement, Quiver could receive up to $120 million in milestone payments plus royalties if Angelini advances drug targets emerging from the collaboration. Financial terms for the upfront payment were not disclosed. Angelini will also receive exclusive access to data generated during the research term.
Europe accelerates next-generation flu vaccines with €225m innovation procurement push
Latest NewsA group of vaccine developers, biotech firms and public health institutes, including Bavarian Nordic and Sanofi, has secured framework contracts under a €225 million EU initiative to accelerate the development of next-generation influenza vaccines.
MoonLake’s sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s Bimzelx
Latest NewsMost inflammatory arthritis patients on MoonLake Immunotherapeutics’ sonelokimab met the response criteria, furthering the Swiss biotech’s attempt to challenge UCB for a blockbuster market.
Syndex Bio raises $15.5M seed and unveils mcPCR platform for DNA methylation analysis
Latest NewsCambridge, UK-based Syndex Bio has announced on Monday the introduction of its proprietary mcPCR™ (methyl-copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) meeting in Orlando, Florida, alongside the close of an oversubscribed $15.5 million seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures and Meltwind Advisory LLP.
Lario Therapeutics wins $2.4m grants to advance calcium channel drugs for Parkinson’s and PTSD
Latest NewsEdinburgh-based Lario Therapeutics has received $2.4 million (approximately €2m) in grant funding from The Michael J. Fox Foundation and Wellcome to expand its drug discovery platform targeting voltage-gated neuronal calcium channels implicated in several central nervous system disorders. The approach is rooted in genetics that the company believes could open new fronts in Parkinson’s disease (PD) and post-traumatic stress disorder (PTSD).
J&J stops enrollment in an AC Immune-partnered Alzheimer trial, but the reason is not yet clear
Latest NewsA pause in the collaborative Alzheimer trial of Johnson & Johnson and partner AC Immune from Switzerland raises some questions. Whether the pause has something to do with overall recruting difficulties or with the application of the drug under investigation is not yet clear.
Solutions-Based Thinking: BioDlink’s Model for Successful CDMO Partnerships
slider, Sponsored PublicationsIn an interview with European Biotechnology Magazine during J.P. Morgan Week in San Francisco, Dr. Jian Zhang, Acting CEO of BioDlink, explains how a partnership-first approach and deep ADC expertise help him offer biotech companies a competitive edge.
Forbion and Sanofi drive $75M investment in COPD biotech Altesa
Latest NewsForbion has led a $75 million investment in Altesa BioSciences, positioning the biotech to run a phase IIb trial in chronic obstructive pulmonary disease (COPD) patients in the second quarter.
Novartis expands cardiovascular pipeline with $1.8bn macrocycle agreement with Unnatural Products
Latest NewsCalifornia-based Unnatural Products, Inc. (UNP) has signed a research collaboration and licensing agreement with Basel-based multinational pharmaceutical company Novartis to develop macrocyclic peptide therapeutics for an undisclosed cardiovascular program.